Immunotherapy
News and reporting on cancer immunotherapy.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Following a recent leadership change, glycoproteomics firm InterVenn Biosciences is reevaluating its commercial strategy and direction.
Foundation Medicine, Natera Launch ctDNA Therapy Response Assay With Medicare Coverage
The tissue-informed ctDNA assay is available to US physicians and is eligible for coverage through both the MolDx and New York's CLEP programs.
Thyroid Cancer Prognostic Signature Developed Using Microenvironment Profiles
Researchers used exome sequencing, RNA sequencing, and other approaches to create a "molecular aggression and prediction" score linked to patient outcomes.
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.